News of Note—APAC adds 50 jobs at Virginia site; New sterile injectable CMO forms

stock market
(Pixabay)

 

> China's WuXi Biologics says it is adding commercial manufacturing to the integrated biologics conjugation solution center it is building in Wuxi, China. Release

> Two U.K. contract manufacturers, Cobra Biologics and Symbiosis Pharmaceutical Services, have invested £4.8 million in a collaboration on viral vector manufacturing. Release 

> After making upgrades, API maker AMPAC Fine Chemicals has reopened a plant in Petersburg, Virginia, that has a 50,000-gallon capacity and will add 150 jobs. Release 

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

> A new CMO has come on the scene with plans to build a $30 million sterile drug manufacturing facility on the West Coast. Story

Read more on

Suggested Articles

A group of drugmakers and others say some federal policies to fight COVID-19 are it making more expensive and harder to get some drugs.

Despite the coronavirus posing a challenge to pharma's supply chain, generics makers could make out well in the ongoing pandemic, one analyst says.

After nearly five years Xellia Pharmaceuticals has started commercial production at former Boehringer Ingelheim sterile injectables plant.